Aktienanalyse zu ICON PLC (ICLR)ICLRICON PLC

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals. It operates in the Healthcare sector (COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH industry).

Currently, ICON PLC (ICLR) is trading at $170.02, with a forward P/E ratio of 16.21, indicating potential value compared to its earnings growth. However, the stock has a recent 5-day change of -1.28% and a year-to-date change of -9.88%, reflecting some volatility. The RSI of 52.06 suggests the stock is neither overbought nor oversold, indicating a neutral momentum. The main risk is its declining net income, which dropped to $7.25 million in Q2 2026 from $104.75 million in Q1 2026, highlighting concerns about profitability. Therefore, while there are positive catalysts like the recent bond offering aimed at reducing debt, the mixed analyst ratings and recent performance suggest holding rather than buying at this time.

15 analysts cover ICLR: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 202.67.